Medical Information

Tenapano tablets, as a novel sodium/hydrogen exchanger 3 (NHE3) inhibitor, effectively control hyperphosphatemia in dialysis patients by inhibiting intestinal phosphorus absorption through a unique mechanism. Its effects are targeted and dose-dependent.

Analysis of the mechanism of action

1. NHE3 inhibition basis

Tenapano selectively blocks the NHE3 transporter protein in intestinal epithelial cells, which plays a central role in sodium and hydrogen ion exchange and alters the acid-base balance of the intestinal microenvironment after inhibition.

2. Phosphorus absorption blockade

By lowering the pH value of the intestinal lumen, phosphate can be converted into insoluble forms, reducing the absorption rate of dietary phosphorus in the intestine. Single administration can reduce phosphorus absorption by 40% -50%.

Pharmacodynamic characteristics

3. Advantages of local effects

The drug works locally in the intestine, with a systemic absorption rate of less than 0.1%, avoiding systemic toxicity, and is particularly suitable for long-term dialysis patients.

4. Dose effect relationship

The degree of decrease in blood phosphorus is positively correlated with dosage. A dose of 800mg/d can reduce blood phosphorus by an average of 1.5-2.0mg/dL, with the maximum effect occurring after 2 weeks of medication.

Clinical management value

5. Combination therapy synergy

Complementary to the traditional phosphorus binding agent mechanism, it can be used in combination to enhance the effect of phosphorus reduction, especially for patients with refractory hyperphosphatemia, which has breakthrough significance.

6. Security advantages

Not interfering with the absorption of other electrolytes, the incidence of hypocalcemia is significantly lower than that of calcium phosphate binders, reducing the medication burden on dialysis patients.

Precautions for medication use

7. Medication time

It must be taken with meals to enhance medication efficacy. Hemodialysis patients should take the medication after dialysis, and peritoneal dialysis patients should avoid dialysis fluid exchange periods.

8. Dose adjustment

The initial dose is 800mg/day, taken in two doses, adjusted every 2-4 weeks according to blood phosphorus levels, with a maximum of 3000mg/day, to avoid self adjustment of dosage.

Interaction between diet and medication

9. Dietary management

It is necessary to strictly limit the intake of high phosphorus foods such as dairy products and nuts, and maintain a balanced low phosphorus diet during medication to enhance efficacy.

10. Medication interval

Take aluminum/magnesium antacids at intervals of 2 hours and iron antacids at intervals of 1 hour to prevent binding reactions from affecting absorption.